Approaches for treating neuropsychiatric symptoms in Parkinson's disease

Neuropsychiatric symptoms in Parkinson's disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As the disease progresses, these symptoms usually become increasingly impairing and are now recognized as having the greatest impact on qu...

Descripción completa

Detalles Bibliográficos
Autores: Rodríguez Antigüedad, Jon|||0000-0002-9316-1772, Olmedo-Saura, Gonzalo|||0000-0003-4864-5548, Pagonabarraga Mora, Javier|||0000-0002-3248-704X, Martínez-Horta, Saul|||0000-0003-0125-7249, Kulisevsky, Jaime|||0000-0003-4870-1431
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:320374
Acceso en línea:https://ddd.uab.cat/record/320374
https://dx.doi.org/urn:doi:10.1177/17562864251336903
Access Level:acceso abierto
Palabra clave:Parkinson's disease
Neuropsychiatric symptoms
Non-motor symptoms
Treatment
Descripción
Sumario:Neuropsychiatric symptoms in Parkinson's disease (PD) are highly prevalent and profoundly disabling, often emerging even before the onset of motor symptoms. As the disease progresses, these symptoms usually become increasingly impairing and are now recognized as having the greatest impact on quality of life not only for patients but also for caregivers. In recent years, there have been significant advances in the diagnosis and management of neuropsychiatric symptoms. However, there are still substantial gaps in therapeutic approaches and algorithms, with limited pharmacological and nonpharmacological treatment options currently available. One of the main reasons for this is the complex molecular and neural bases of these symptoms, which involve both dopaminergic and nondopaminergic neurotransmission systems and extend far beyond the nigrostriatal pathway. As a result, the drugs currently recommended for treating neuropsychiatric symptoms in PD are few and supported by limited evidence. In this context, the experience of the treating neurologist remains critical in selecting the most appropriate individualized therapy. The aim of this paper is to review the available therapeutic options and provide an overview of current research efforts, particularly those focusing on pharmacological treatments.